Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.67 |
| ▸ | CA1 | P00915 | 3/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.67 |
| ▸ | CA3 | P07451 | 1/20 | 0.67 |
| ▸ | AR | P10275 | 1/20 | 0.67 |
| ▸ | CA4 | P22748 | 1/20 | 0.67 |
| ▸ | CA6 | P23280 | 1/20 | 0.67 |
| ▸ | CA5A | P35218 | 1/20 | 0.67 |
| ▸ | CA7 | P43166 | 1/20 | 0.67 |
| ▸ | CA9 | Q16790 | 1/20 | 0.67 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.67 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23643377 | 1.00 | CA2 (0.67) | CA2CA1CA12CA3AR | |
| SCHEMBL23643348 | 1.00 | CA2 (0.67) | CA2CA1CA12CA3AR | |
| SCHEMBL18656499 | 0.89 | CA2 (0.70) | CA2CA1CA12CA3AR | |
| SCHEMBL18656504 | 0.89 | CA2 (0.70) | CA2CA1CA12CA3AR | |
| SCHEMBL19821489 | 0.84 | CA2 (0.73) | CA2CA1CA12CA3AR | |
| SCHEMBL18651244 | 0.83 | CA2 (0.61) | CA2CA1CA12CA3AR | |
| SCHEMBL18651391 | 0.83 | CA2 (0.61) | CA2CA1CA12CA3AR | |
| SCHEMBL18656673 | 0.83 | CA2 (0.70) | CA2CA1CA12CA3AR | |
| SCHEMBL13852712 | 0.82 | CA2 (0.80) | CA2CA1CA12CA3AR | |
| SCHEMBL13852720 | 0.82 | CA2 (0.80) | CA2CA1CA12CA3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063035-A1 | CARBONIC ANHYDRASE INHIBITORS DERIVATIVES | NICOX S.A. (FR) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063035-A1 | CARBONIC ANHYDRASE INHIBITORS DERIVATIVES | CA4, CA2, CA9 | CA2 2/4885CA1 71/4885CA12 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.